Description of Ani Pharmaceuticals Inc's Business Segments

Comprehensive Overview of Ani Pharmaceuticals Inc: Segments, Products, and Services

Ani Pharmaceuticals Inc. is a notable player in the specialty pharmaceutical sector, offering a diverse array of products and services across multiple therapeutic landscapes, encompassing womens health, oncology, ophthalmology, and veterinary medicine. The company’s dedication to transforming patient care through innovative and premium-quality pharmaceutical solutions is evident in their extensive portfolio.

Segments

1. Branded Pharmaceuticals:
- This segment is dedicated to the research, development, manufacturing, marketing, and distribution of branded medications targeted at specific therapeutic areas.
- Key Products:
- Elestrin: An estrogen topical gel formulated to alleviate menopausal symptoms like hot flashes, night sweats, and vaginal dryness.
- Ovaban: A synthetic progestin used in veterinary medicine, particularly for treating reproductive disorders in female dogs, including false pregnancy and cystic endometrial hyperplasia.
- Luveniq: Specifically developed for Hunter syndrome, a rare genetic disorder; it addresses the deficiency of the enzyme iduronate-2-sulfatase.
- Cortrophin: Utilized in the management of various autoimmune and inflammatory conditions such as multiple sclerosis, lupus, and allergies.

2. Generic Pharmaceuticals:
- This segment focuses on the development, manufacturing, and marketing of generic medications, providing cost-effective alternatives for various therapeutic areas.
- Key Products:
- Hydrocortisone: Used in treating skin conditions, including eczema, psoriasis, and dermatitis, this medication is integral in anti-inflammatory treatments.
- Diclofenac/Misoprostol: Combines an anti-inflammatory with a protective agent, recommended for conditions like rheumatoid arthritis and osteoarthritis.
- Methimazole: Employed in managing hyperthyroidism, helping regulate thyroid hormone production in patients.

3. Contract Manufacturing:
- Ani Pharmaceuticals extends its expertise by offering contract manufacturing services to other pharmaceutical companies, ensuring a streamlined process from drug development to final product packaging.
- Key Services:
- Preformulation: Conducting numerous experimental studies to evaluate the physicochemical properties of drug substances in order to identify optimal candidates for further development.
- Formulation: The creation of a final drug product involves rigorous processes such as granulation, blending, compression, coating, and packaging.
- Clinical Trial Material Manufacturing: Producing small batches of drug products tailored for clinical trials to evaluate their safety and efficacy.
- Scale-Up: This involves transferring lab-scale manufacturing processes to commercial levels, ensuring products can be produced safely and sustainably.
- Commercial Manufacturing: This encompasses the full production cycle of large batches of pharmaceuticals for market distribution, incorporating both upstream and downstream manufacturing processes.

Products

- Elestrin: A convenient topical gel providing effective symptom relief for menopausal women, focusing on improving their quality of life.
- Ovaban: An important veterinary medication that addresses reproductive hormonal issues, effectively supporting the health and wellbeing of female dogs.
- Luveniq: Addresses the needs of patients suffering from Hunter syndrome, targeting the metabolic deficiencies associated with the disorder.
- Cortrophin: A versatile medication utilized in treating a range of health conditions, emphasizing its role in the management of immune and inflammatory diseases.
- Hydrocortisone: Widely recognized for its efficacy in various skin-related conditions, playing a crucial role in dermatological therapy.
- Diclofenac/Misoprostol: This formulation provides both pain relief and gastrointestinal protection, making it valuable in orthopedic and rheumatological treatments.
- Methimazole: Critical in the management of hyperthyroidism, offering a therapeutic option to balance thyroid hormone levels.

Services

- Preformulation Services: A comprehensive suite of studies aimed at characterizing drug substances, facilitating the progression of promising compounds to development stages.
- Formulation Development: An integrated approach that ensures drug products are formulated efficiently and effectively, ready for clinical and commercial phases.
- Clinical Trial Material Manufacturing: Focused on the production of clinical trial materials that adhere to regulatory standards, ensuring the reliability of trial data.
- Scale-Up Services: Careful processes designed to transition from laboratory production to industrial-scale manufacturing, maintaining product integrity and safety.
- Commercial Manufacturing: High-volume production capabilities ensure that pharmaceuticals reach the market efficiently and meet demand, with a robust quality assurance framework.

Conclusion

Ani Pharmaceuticals Inc. stands out as a comprehensive provider of pharmaceutical solutions, underpinned by a commitment to innovation and quality. By combining a diverse portfolio of branded and generic products with extensive contract manufacturing capabilities, Ani Pharmaceuticals continues to play a pivotal role in enhancing healthcare outcomes globally, responding to the evolving needs of patients and healthcare providers across a range of therapeutic areas. Their strategic focus on various segments ensures they remain at the forefront of the pharmaceutical industry.

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Composition of Ani Pharmaceuticals Inc Revenues by Segments


Sales of Cortrophin Gel	72.26 %	of total Revenue
Sales of ILUVIEN and YUTIQ	14.27 %	of total Revenue
Total sales of rare disease pharmaceutical products	86.53 %	of total Revenue
Sales of Established Brands	9.07 %	of total Revenue
Sales of Established Brand Royalties and Other Revenues	14.76 %	of total Revenue
Total Sales of Rare Disease and Brands	110.37 %	of total Revenue
Sales of generic pharmaceutical products	76.85 %	of total Revenue
Sales of Generic Other Revenues	2.04 %	of total Revenue
Total Sales of Generics and Other	78.89 %	of total Revenue
Brands	4.47 %	of total Revenue
Generics and Other	78.89 %	of total Revenue
Rare Disease and Brands	110.37 %	of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments	Revenues (in millions $)	% (of total Revenues)
Sales of Cortrophin Gel	192.25	72.26 %
Sales of ILUVIEN and YUTIQ	37.97	14.27 %
Total sales of rare disease pharmaceutical products	230.22	86.53 %
Sales of Established Brands	24.14	9.07 %
Sales of Established Brand Royalties and Other Revenues	39.27	14.76 %
Total Sales of Rare Disease and Brands	293.63	110.37 %
Sales of generic pharmaceutical products	204.45	76.85 %
Sales of Generic Other Revenues	5.42	2.04 %
Total Sales of Generics and Other	209.88	78.89 %
Brands	11.90	4.47 %
Generics and Other	209.88	78.89 %
Rare Disease and Brands	293.63	110.37 %
Total	266.04	100 %

Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment	Y/Y Revenue %	Q/Q Revenue %
Sales of Cortrophin Gel	-	-
Sales of ILUVIEN and YUTIQ	-	-
Total sales of rare disease pharmaceutical products	-	-
Sales of Established Brands	-	-
Sales of Established Brand Royalties and Other Revenues	-	-
Total Sales of Rare Disease and Brands	-	-
Sales of generic pharmaceutical products	-	-
Sales of Generic Other Revenues	-	-
Total Sales of Generics and Other	-	-
Brands	-9.81 %	-3.47 %
Generics and Other	122.77 %	92.16 %
Rare Disease and Brands	150.63 %	128.97 %
Total	25.87 %	12.04 %

Q2 three months ended (Jun 30 2026)
Income by Business Segments	Income (in millions $)	% (Profit Margin)
Generics and Other	76.81	36.6 %
Rare Disease and Brands	88.60	30.17 %
Segment Reporting, Reconciling Item, Corporate Nonsegment	-86.06	-
Total	23.00	8.65 %

Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment	Y/Y Income %	Q/Q Income %
Generics and Other	101.19 %	90.52 %
Rare Disease and Brands	200.72 %	144.39 %
Segment Reporting, Reconciling Item, Corporate Nonsegment	-	-
Total	169.04 %	-22.01 %

Annual Report on Ani Pharmaceuticals Inc Divisions, Sales by Country


Brands	6.94 %	of total Revenue
Generics and Other	45.22 %	of total Revenue
Rare Disease and Brands	54.78 %	of total Revenue
Rare Disease total net revenues	47.84 %	of total Revenue
Cortrophin Gel	39.37 %	of total Revenue
ILUVIEN and YUTIQ	8.48 %	of total Revenue
Rare Disease and Brands total net revenues	54.79 %	of total Revenue
Generics and Other total net revenues	45.21 %	of total Revenue
Generic pharmaceutical products	43.48 %	of total Revenue
Royalties and other pharmaceutical services	1.73 %	of total Revenue
Sales of contract manufactured products	0.27 %	of total Revenue
Performance obligations transferred at a point in time	100 %	of total Revenue
United States	96.5 %	of total Revenue
International	3.5 %	of total Revenue

Twelve months ended 2025
ANIP s Annual Revenue by Geography and Business Segments	Sales (in millions $)	% (of total Sales)
Brands	61.31	6.94 %
Generics and Other	399.43	45.22 %
Rare Disease and Brands	483.93	54.78 %
Total	883.37	100 %
Rare Disease total net revenues	422.65	47.84 %
Cortrophin Gel	347.78	39.37 %
ILUVIEN and YUTIQ	74.87	8.48 %
Rare Disease and Brands total net revenues	483.95	54.79 %
Generics and Other total net revenues	399.41	45.21 %
Generic pharmaceutical products	384.11	43.48 %
Royalties and other pharmaceutical services	15.30	1.73 %
Sales of contract manufactured products	2.40	0.27 %
Performance obligations transferred at a point in time	883.37	100 %
United States	852.44	96.5 %
International	30.92	3.5 %

Twelve months ended 2025
ANIP s Annual Income by Country and Business Segments	Income (in millions $)	% (Profit Margin)
Total	78.34	8.87 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments	% Y/Y Sales Growth	% Y/Y Income Growth
Brands	-5.31 %	-
Generics and Other	24.81 %	-
Rare Disease and Brands	64.41 %	-
Total	43.78 %	-
Rare Disease total net revenues	84.08 %	-
Cortrophin Gel	75.57 %	-
ILUVIEN and YUTIQ	137.57 %	-
Rare Disease and Brands total net revenues	64.42 %	-
Generics and Other total net revenues	24.8 %	-
Generic pharmaceutical products	27.61 %	-
Royalties and other pharmaceutical services	-19.59 %	-
Sales of contract manufactured products	242.86 %	-
Performance obligations transferred at a point in time	43.78 %	-
United States	40.9 %	-
International	229.42 %	-

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.